Figure 3
From: The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
Progression-free survival curves (PFS) with number at risk stratified by FRS2α intensity. The Ariol imaging platform was used to stratify the specimens based on intensity of immunofluorescence staining for FRS2α. Non-tumor tissue was excluded from analysis. The differences across FRS2α intensity strata were not statistically significant in univariate analysis; P = 0.2610.